JP2018533579A - 高分子量かつ密な被覆を有する粘液浸透粒子 - Google Patents

高分子量かつ密な被覆を有する粘液浸透粒子 Download PDF

Info

Publication number
JP2018533579A
JP2018533579A JP2018522081A JP2018522081A JP2018533579A JP 2018533579 A JP2018533579 A JP 2018533579A JP 2018522081 A JP2018522081 A JP 2018522081A JP 2018522081 A JP2018522081 A JP 2018522081A JP 2018533579 A JP2018533579 A JP 2018533579A
Authority
JP
Japan
Prior art keywords
peg
poly
mucus
particles
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018522081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533579A5 (cg-RX-API-DMAC10.html
Inventor
ジャスティン ヘインズ，
ジャスティン ヘインズ，
カサリーナ マイセル，
カサリーナ マイセル，
ローラ エム． エンサイン，
ローラ エム． エンサイン，
リチャード コーン，
リチャード コーン，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2018533579A publication Critical patent/JP2018533579A/ja
Publication of JP2018533579A5 publication Critical patent/JP2018533579A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
JP2018522081A 2015-10-30 2016-10-31 高分子量かつ密な被覆を有する粘液浸透粒子 Pending JP2018533579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248432P 2015-10-30 2015-10-30
US62/248,432 2015-10-30
PCT/US2016/059661 WO2017075565A1 (en) 2015-10-30 2016-10-31 Mucus penetrating particles with high molecular weight and dense coatings

Publications (2)

Publication Number Publication Date
JP2018533579A true JP2018533579A (ja) 2018-11-15
JP2018533579A5 JP2018533579A5 (cg-RX-API-DMAC10.html) 2019-12-12

Family

ID=57288512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522081A Pending JP2018533579A (ja) 2015-10-30 2016-10-31 高分子量かつ密な被覆を有する粘液浸透粒子

Country Status (8)

Country Link
US (1) US10668025B2 (cg-RX-API-DMAC10.html)
EP (1) EP3368008A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018533579A (cg-RX-API-DMAC10.html)
KR (1) KR20180075650A (cg-RX-API-DMAC10.html)
CN (1) CN108472250A (cg-RX-API-DMAC10.html)
AU (1) AU2016343840A1 (cg-RX-API-DMAC10.html)
CA (1) CA3003733C (cg-RX-API-DMAC10.html)
WO (1) WO2017075565A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130270A (ja) * 2021-02-25 2022-09-06 シンバイオシス株式会社 腸管吸収用補助剤及びその利用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
CA2859046C (en) * 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
LT3820439T (lt) 2018-09-11 2022-01-10 Lead Biotherapeutics Ltd. Mukoadhezinė dispersinė nanodalelių sistema ir jos gamybos būdas
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
JP2023529194A (ja) * 2020-06-11 2023-07-07 ヤンセン バイオテツク，インコーポレーテツド 局所薬物送達のための自己包埋粒子の制御放出

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505855A (ja) * 2011-12-14 2015-02-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
JP2010502713A (ja) * 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
WO2012039979A2 (en) * 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
ES2385995B2 (es) * 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
US9415020B2 (en) * 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CA2872519C (en) * 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505855A (ja) * 2011-12-14 2015-02-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130270A (ja) * 2021-02-25 2022-09-06 シンバイオシス株式会社 腸管吸収用補助剤及びその利用方法
JP7842983B2 (ja) 2021-02-25 2026-04-09 学校法人神戸学院 腸管吸収用補助剤及びその利用方法

Also Published As

Publication number Publication date
US20180221293A1 (en) 2018-08-09
US10668025B2 (en) 2020-06-02
CN108472250A (zh) 2018-08-31
CA3003733C (en) 2021-04-20
CA3003733A1 (en) 2017-05-04
EP3368008A1 (en) 2018-09-05
WO2017075565A1 (en) 2017-05-04
AU2016343840A1 (en) 2018-06-07
KR20180075650A (ko) 2018-07-04

Similar Documents

Publication Publication Date Title
CA3003733C (en) Mucus penetrating particles with high molecular weight and dense coatings
US9415020B2 (en) Nanoparticle formulations with enhanced mucosal penetration
US20210196829A1 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
Ahmed et al. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery
Nafee et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors
Sonaje et al. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins
Cote et al. Nanomedicine for drug delivery throughout the alimentary canal
WO2021057007A1 (zh) 一种雷帕霉素纳米缓释剂及其制备方法
Luan et al. Mannosamine-engineered nanoparticles for precision rifapentine delivery to macrophages: advancing targeted therapy against mycobacterium tuberculosis
Garg et al. Mucoadhesive drug delivery system in chronic respiratory diseases
US12409146B2 (en) Solid lipid nanoparticle for intracellular release of active substances and method for production the same
Hubbard Transepithelial transport of PAMAM dendrimers across isolated intestinal tissue
Kuehl Engineering Particles and Polymers to Improve Pulmonary Therapeutics
Kleinebudde et al. Pellets–A universal tool for oral drug delivery
HK1215380B (en) Nanoparticle formulations with enhanced mucosal penetration
HK1203052B (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210426